Loading...
OTCM
HOFBF
Market cap65mUSD
Dec 15, Last price  
0.17USD
Name

Hofseth Biocare ASA

Chart & Performance

D1W1MN
OTCM:HOFBF chart
P/E
—
P/S
2.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.26%
Rev. gr., 5y
29.73%
Revenues
254m
-1.16%
171,0001,183,00026,015,00062,936,00019,769,00055,137,00020,204,000118,476,00060,740,00067,778,00069,252,00087,616,000120,448,000194,874,000257,417,000254,430,000
Net income
-135m
L+9.30%
-9,387,000-19,036,000-73,860,000-52,136,000-66,918,000-100,194,000-147,450,000-16,475,000-84,768,000-89,209,000-102,090,000-126,463,000-137,389,000-106,683,000-123,405,000-134,881,000
CFO
-38m
L+293.09%
-12,445,000-19,470,000-48,006,000-83,652,000-62,257,0007,967,000-67,226,000-25,485,000-28,625,000-31,060,000-61,632,000-61,779,000-45,168,0002,761,000-9,780,000-38,444,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.
URL
https://hofsethbiocare.com
IPO date
Dec 02, 2011
Employees
56
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT